
<p>Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States</p>
Author(s) -
Tiffany P. Quock,
Tingjian Yan,
Ryan Tieu,
Anita D’Souza,
Michael S. Broder
Publication year - 2019
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s207127
Subject(s) - medicine , cardiac amyloidosis , amyloidosis , al amyloidosis , disease , cardiac dysfunction , intensive care unit , amyloid fibril , heart failure , immunoglobulin light chain , intensive care medicine , antibody , amyloid β , immunology
Cardiac dysfunction is common in amyloid light-chain (AL) amyloidosis, a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to examine economic/clinical disease burden in hospitalized cardiac amyloidosis patients.